Biomedcode - Beck to Home page

News

December 04th, 2012 
Open research positions at Biomedcode Hellas SA

Positions for two doctoral students are available at Biomedcode under European FP7 Marie Curie Initial Training Networks aDDRess (http://www.itn-address.gr/) and CodeAge (http://www.itn-codeage.eu/). The projects aim at understanding the role of DNA repair and damage response mechanisms in disease and aging using mouse models. Specifically, one project will focus on the identification of novel inflammatory biomarkers in NER progeria, while the second will deal with comprehensive immunophenotyping of progeroid animal models. Positions are for 36 months and available immediately.

 

The projects offer very competitive remuneration and the opportunity to perform research in a highly dynamic R&D environment, in the context of a comprehensive training program that combines top-level, state-of-the-art interdisciplinary research ranging from basic molecular mechanisms and ‘omics’ level understanding to translational research and clinical applications.

 

Successful candidates should have a post-graduate degree (M.Sc. or equivalent) in Life Sciences or related fields with specialisation preferably in molecular biology  or immunology, and at least 2 years of laboratory experience in an academic or  biotech/pharmaceutical setting (including Master's thesis if it includes bench work). Experience with animal handling, pharmacology, immunology, gene expression studies, or histopathology will be considered an asset. Excellent oral and writing skills in English are also required.

 

Specific Marie-Curie requirements:

Candidates must be in the first four years of their research careers and have not yet been awarded a doctoral degree. At the time of recruitment candidates must not have resided or carried out their main activity (work, studies, etc) in Greece for more than 12 months in the 3 years immediately prior to the reference date. Short stays such as holidays and/or compulsory national service are not taken into account.

 

Candidates should email a cover letter outlining their interests, motivation and areas of expertise (maximum 1 page long) together with a detailed curriculum vitae including contact information of two or more referees to grants@biomedcode.com . Please send a single pdf file with all of the above information, named with your last and first name (e.g. ObamaBarack.pdf)

 

Deadline for Applications: January 1, 2013.

December 03rd, 2012 
Biomedcode is seeking an experienced Project Manager for European and National (ESPA) biomedical research programs

The successful candidate will support the financial and administrative management of the company's R&D programs, in collaboration with its Financial Department and Management team. Her/his responsibilities will include financial and administrative monitoring of projects, preparation of financial progress reports, verification of cost eligibility, preparation and drafting of technical annex amendments, communication with funding agencies on financial matters, consulting to the company's Management on financial and tax issues relating to current and new research programs, drafting the financial parts of new grant applications and overall supervision and execution of project budget plans.

Candidates must hold a higher education degree and should have knowledge in economics and/or financing.  Experience or studies in biomedical sciences and/or business administration/marketing will be considered an asset. The successful candidate should have excellent oral and written communication skills in Greek and English, and should be an advanced user of project and financial management software. Previous experience in managing European and Greek (ESPA) national programs is absolutely required.

Competitive salary will depend on qualifications and experience.

Applications should include a curriculum vitae and a letter of interest outlining the candidate's qualifications, and previous work experience. The CV and letter should be sent electronically to grants@biomedcode.com in a single pdf file named with the candidate's last and first name (e.g. ObamaBarack.pdf).

Deadline for applications: January 1st, 2013

September 01st, 2012 
Zyngenia, Inc. reports successful preclinical evaluation of a novel bispecific antibody targeting TNF and Ang2 in Biomedcode’s Tg197 model.

            

Zyngenia,Inc. has developed a proprietary Zybody™ platform technology that allows single-protein combination therapeutics. In   the September issue of the journal mAbs, Zyngenia reports successful preclinical evaluation of a bispecific Zybody™ targeting Ang2 and TNF in Biomedcode’s Tg197 model of arthritis. The data establish increased efficacy of dual TNF and Ang-2 antagonism as measured by significant reductions in clinical and histopathological scores of disease, compared to single anti-TNF treatment.

June 14th, 2012 
Biomedcode is a partner in aDDRess an international Initial Training Network studying chromatin dynamics and the DNA damage response

The aDDRess (http://www.itn-address.gr/) Initial Training Network (ITN) was carefully designed to create a joint European program of research and training activities with a core intellectual focus on the impact of Chromatin Dynamics on the DNA damage Response (DDR) (aDDRess). The Network addresses a major research topic with great socioeconomic impact in Europe, builds a well-structured multi-disciplinary European science area and strong links to the industry, thereby providing young researchers with a unique skill set that enhances their future career prospects.

May 31st, 2012 
Biomedcode is a partner in CodeAge an international Initial Training Network studying the role of Chronic DNA damage in Ageing and Age-related pathology

CodeAge (http://www.itn-codeage.eu/) is a multi-disciplinary European training and research network focusing on molecular, cellular and systems biology aspects of ageing that is specifically complemented with SME driven research on genomics, analytical proteomics, and disease model testing.
In combination with the expected identification of accessible biomarkers, allowing monitoring of intervention studies, this program will further contribute to a better knowledge-driven drug development to prevent or counteract age-associated pathologies in order to improve the quality of life to the elderly.

February 21st, 2012 
Biomedcode is a participant in TARKINAID a €4 million international research project to fight chronic autoimmune diseases

TARKINAID, an international consortium of 11 class-leading academic and industrial research organisations from Europe and Brazil, kicked off to a €4 million research project to develop new ways of treating chronic autoimmune diseases such as rheumatoid arthritis.

 

The goal of the four-year project is to develop a novel class of drug candidates that can efficiently treat animal models of chronic autoimmune diseases and can enter clinical testing towards the end of the four-year project period. The total budget of the project is €4 million, €3 million of which is provided by the 7th Framework Programme of the European Union.

 

The consortium comprises a team of five highly competitive European universities and research institutions and two top Brazilian groups. The project is reinforced by three biotech companies for promoting translational research and a company managing EU-funded research projects. TARKINAID is anticipated to strengthen ties between the EU and Brazil, one of the World's largest emerging economies with significant expertise in testing animal models of inflammatory diseases.

 

TARKINAID Participants:
Semmelweis University, Budapest, Hungary (Coordinator)
Ludwig-Maximilians Universität München, Germany
Università degli Studi di Verona, Italy
Centre National de la Recherche Scientifique, Toulouse, France
Vichem Chemie Research Ltd., Budapest, Hungary
Universitätsklinikum Freiburg, Germany
Universidade Federal do Rio de Janeiro, Brazil
Biomedcode Hellas SA, Athens, Greece
Ambiotis SAS, Toulouse, France
Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil
ALTA Ricerca e Sviluppo in Biotecnologie S.r.l.u., Siena, Italy
August 30th, 2010 
Biomedcode is a participant of the TheRalead consortium that received 1.9 million € funding from the Ministry of Education

Biomedcode is a participant of the TheRAlead proposal, submitted under GSRT's (Greek General Secretariat of Research and Technology) SYNERGASIA action. The program will be funded with 1.8 million euros over the next 4 years.

 

TheRAlead aims to bridge the gap between target identification and pre-clinical validation exploiting  a “hit to lead” pipeline, by integrating state-of-the-art tools and expertise of academic and industrial partners to address the development of novel therapeutic compounds for rheumatoid arthritis. The project will exploit an interdisciplinary approach consisting of structure based drug design, organic synthesis, in vitro screening, cellular assays, in silico optimisation, and validation in animal models of arthritis (a key task of Biomedcode). TheRAlead will capitalize on the scientific and technological excellence of its partners - two research institutes (The Coordinator BSRC Fleming and CERETETH), a university (Agricultural University of Athens), an SME (Biomedcode) and a pharmaceutical company (Pharmathen) - linked together by their joint interest in drug discovery and development. The Consortium aims to promote intense collaborative research and exchange of know-how to complete a successful drug discovery process for Rheumatoid Arthritis including early drug development stages, that is expected to yield several commercial opportunities for exploitation of results.

June 01st, 2010 
Successful completion of AVENT preclinical efficacy trial using Biomedcode's humanized animal model of arthritis

AVESTHAGEN announced that it has successfully completed the pre-Clinical efficacy trial for one of its biosimilar drugs AVENT™ at Biomedcode Hellas S.A. AVENT™ is the biosimilar version of a fully humanized soluble tumor necrosis factor (TNF) receptor. The results indicate that AVENT™ developed by Avesthagen is effective in addressing arthritic conditions in the human TNF Tg197 mouse model of arthritis. The global sales of the commercially available reference drug were around $ 6.58 billion in 2009.
AVENT™ is indicated for reducing signs and symptoms, in patients with moderate to severe Rheumatoid Arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and Juvenile Idiopathic Arthritis.
March 16th, 2010 
Viron Therapeutics Inc. announced successful preclinical testing of VT-346 using Biomedcode's humanized model of arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the human TNF Tg197 gold standard transgenic mouse model for arthritis. Pre-clinical testing of this compound was conducted by BioMedCode, a recognized leader in the use of this transgenic model.

March 01st, 2010 
In February 2010, Biomedcode agreed the non-exclusive out-licensing of one of its proprietary animal models to AstraZeneca

In February 2010, Biomedcode agreed the non-exclusive out-licensing of one of its proprietary animal models to AstraZeneca under undisclosed terms. This out-licensing further demonstrates the value of Biomedcode’s genetic models as platforms for the validation and evaluation of novel therapeutic approaches and technologies.

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com